Joseph John Metzger

US Patent:

20120165503, Jun 28, 2012

Filed:

Dec 18, 2009

Appl. No.:

13/202524

Inventors:

Paul E. Carrington - Rahway NJ, US
George Eiermann - Rahway NJ, US
Donald Marsh - Rahway NJ, US
Joseph Metzger - Rahway NJ, US
Alessandro Pocai - Rahway NJ, US
Ranabir Sinha Roy - Rahway NJ, US
Bianchi Bianchi - Pomezia, IT
Paolo Ingallinella - Pomezia, IT
Antonello Pessi - Pomezia, IT
Alessia Santoprete - Pomezia, IT
Elena Capito - Pomezia, IT
Richard Dimarchi - Indianapolis IN, US
Brian Ward - Bloomington IN, US

International Classification:

C07K 14/605

US Classification:

530308

Abstract:

Peptide analogs of oxyntomodulin (OXM, glucagon-37), which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to act as a dual GLP-1/glucagon receptor (GCGR) agonistm are described. The peptide analogs are useful for treatment of metabolic disorders such as diabetes and obesity.

US Patent:

20150307580, Oct 29, 2015

Filed:

Apr 14, 2015

Appl. No.:

14/686760

Inventors:

- Rahway NJ, US
- Roma, IT
- Indianapolis IN, US
Joseph M. METZGER - Rahway NJ, US
Alessandro POCAI - Rahway NJ, US
Ranabir SINHA ROY - Rahway NJ, US
Elisabetta BIANCHI - Pommezia, IT
Paolo INGALLINELLA - Pommezia, IT
Antonello PESSI - Pommezia, IT
Alessia PRETE - Pommezia, IT
Elena CAPITO - Pommezia, IT
Richard DIMARCHI - Indianapolis IN, US
Brian WARD - Bloomington IN, US

International Classification:

C07K 14/605

Abstract:

Peptide analogs of oxyntomodulin (OXM, glucagon-37), which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to act as a dual GLP-1/glucagon receptor (GCGR) agonist are described. The peptide analogs are useful for treatment of metabolic disorders such as diabetes and obesity.